Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection

Papillomavirus Research

Volumn 1, Issue , 2015, Pages 3-11

  Cullen, Michael ^a,b   Boland, Joseph F ^a,b   Schiffman, Mark ^a   Zhang, Xijun ^a,b   Wentzensen, Nicolas ^a   Yang, Qi ^a,b   Chen, Zigui ^e   Yu, Kai ^a   Mitchell, Jason ^a,b   Roberson, David ^a,b   Bass, Sara ^a,b   Burdette, Laurie ^a,b   Machado, Moara ^c   Ravichandran, Sarangan ^b   Luke, Brian ^b   Machiela, Mitchell J ^a   Andersen, Mark ^d   Osentoski, Matt ^d   Laptewicz, Michael ^d   Wacholder, Sholom ^a   Feldman, Ashlie ^a,b   Raine Bennett, Tina ^f   Lorey, Thomas ^f   Castle, Philip E ^e,g   Yeager, Meredith ^a,b   Burk, Robert D ^e   Mirabello, Lisa ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d Thermo Fisher Scientific   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f KAISER PERMANENTE   (United States)

^g Global Coalition Against Cervical Cancer   (United States)

Author keywords

HPV epidemiology; HPV genomics; HPV16

Indexed keywords

ARTICLE; BINDING SITE; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; CYTOLOGY; DNA ISOLATION; GENE SEQUENCE; GENETIC VARIABILITY; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NEXT GENERATION SEQUENCING; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELIABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; UTERINE CERVIX CANCER; VIRUS GENOME; VIRUS LOAD;

EID: 84947930704     PISSN: None     EISSN: 24058521     Source Type: Journal    
DOI: 10.1016/j.pvr.2015.05.004     Document Type: Article

References (49)

1. Bruni L., et al. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis. 2010, 202:1789-1799.
2. Forman D., et al. Global burden of human papillomavirus and related diseases. Vaccine 2012, 30(Suppl. 5):F12-F23.
3. Schiffman M., et al. Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
4. Jemal A., et al. Global cancer statistics. CA: Cancer J. Clin. 2011, 61:69-90.
5. Ho G., et al. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 1998, 338:423-428.
6. McCredie M., et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2008, 9:425-434.
7. Bernard H.U., et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
8. Guan P., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int. J. Cancer 2012, 131:2349-2359.
9. de Sanjose S., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010, 11:1048-1056.
10. Bouvard V., et al. A review of human carcinogens-Part B: Biological agents. Lancet Oncol. 2009, 10:321-322.
11. Burk R.D., Chen Z., Van Doorslaer K. Human papillomaviruses: genetic basis of carcinogenicity. Public Health Genomics 2009, 12:281-290.
12. Burk R.D., Harari A., Chen Z. Human papillomavirus genome variants. Virology 2013, 445:232-243.
13. Xi L.F., et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol. Biomarkers Prev. 2007, 16:4-10.
14. Hildesheim A., et al. Human papillomavirus type 16 variants and risk of cervical cancer. J. Natl. Cancer Inst. 2001, 93:315-318.
15. Pientong C., et al. Association of human papillomavirus type 16 long control region mutation and cervical cancer. Virol. J. 2013, 10:30.
16. Cornet I., et al. HPV16 genetic variation and the development of cervical cancer worldwide. Br. J. Cancer 2013, 108:240-244.
17. Gheit T., et al. Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women. Cancer Epidemiol. Biomarkers Prev. 2011, 20:1315-1321.
18. Schiffman M., et al. A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia. Cancer Res. 2010, 70:3159-3169.
19. Sichero L., et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int. J. Cancer 2007, 120:1763-1768.
20. Villa L.L., et al. Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J. Gen. Virol. 2000, 81:2959-2968.
21. Zuna R.E., et al. Association of HPV16 E6 variants with diagnostic severity in cervical cytology samples of 354 women in a US population. Int. J. Cancer 2009, 125:2609-2613.
22. Smith B., et al. Sequence imputation of HPV16 genomes for genetic association studies. PLoS ONE 2011, 6:e21375.
23. Rothberg J.M., et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011, 475:348-352.
24. Castle P., et al. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol. Biomarkers Prev. 2011, 20:946-953.
25. Castle P.E., et al. Human papillomavirus (HPV) genotypes in women with cervical precancer and cancer at Kaiser Permanente Northern California. Cancer Epidemiol. Biomarkers Prev. 2011, 20:946-953.
26. Burk R.D., et al. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J. Infect. Dis. 1996, 174:679-689.
27. Castle P.E., et al. Comparisons of HPV DNA detection by MY09/11 PCR methods. J. Med. Virol. 2002, 68:417-423.
28. Gravitt P.E., et al. High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident disease. Int. J. Cancer 2007, 121:2787-2793.
29. Chen Z., et al. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J. Virol. 2005, 79:7014-7023.
30. Chen Z., et al. Evolution and taxonomic classification of human papillomavirus 16 (HPV16)-related variant genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS ONE 2011, 6:e20183.
31. Katoh K., Toh H. Parallelization of the MAFFT multiple sequence alignment program. Bioinformatics 2010, 26:1899-1900.
32. Stamatakis A. RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. Bioinformatics 2006, 22:2688-2690.
33. Tamura K., et al. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28:2731-2739.
34. G. Myers, et al., Human papillomaviruses 1997: a compilation and analysis of nucleic acid and amino acid sequences, in: HPV Sequence Database 1997: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
35. DePristo M.A., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 2011, 43:491-498.
36. P. Cingolani, et al., A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w(1118); iso-2; iso-3, Fly. vol. 6 (2012) pp. 80-92.
37. Thorvaldsdóttir H., Robinson J.T., Mesirov J.P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinf. 2013, 14:178-192.
38. Mirabello L., et al. Methylation of human papillomavirus type 16 genome and risk of cervical precancer in a costa rican population. JNCI 2012, 104:556-565.
39. Wentzensen N., et al. Methylation of HPV18, HPV31, and HPV45 genomes and cervical intraepithelial neoplasia grade 3. J. Natl. Cancer Inst. 2012, 104:1738-1749.
40. Mirabello L., et al. Elevated methylation of HPV16 DNA is associated with the development of high grade cervical intraepithelial neoplasia. Int. J. Cancer 2013, 132:1412-1422.
41. Mirabello L., et al. HPV16 methyl-haplotypes determined by a novel next-generation sequencing method are associated with cervical precancer. Int. J. Cancer 2015, 136:E146-E153.
42. Clarke M.A., et al. Human papillomavirus DNA methylation as a potential biomarker for cervical cancer. Cancer Epidemiol. Biomarkers Prev. 2012, 21:2125-2137.
43. Geraets D.T., et al. Long-term follow-up of HPV16-positive women: persistence of the same genetic variant and low prevalence of variant co-infections. PLoS ONE 2013, 8:e80382.
44. Swan D.C., et al. Human papillomavirus type 16 variant assignment by pyrosequencing. J. Virol. Methods 2006, 136:166-170.
45. van der Marel J., et al. Molecular mapping of high-grade cervical intraepithelial neoplasia shows etiological dominance of HPV16. Int. J. Cancer 2012, 131:E946-E953.
46. Quint W., et al. One virus, one lesion-individual components of CIN lesions contain a specific HPV type. J. Pathol. 2012, 227:62-71.
47. Wentzensen N., Vinokurova S., Doeberitz M.v.K. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 2004, 64:3878-3884.
48. Xu B., et al. Multiplex identification of human papillomavirus 16 DNA integration sites in cervical carcinomas. PLoS ONE 2013, 8:e66693.
49. el Awady M., Kaplan J., O'Brien S., Burk R. Molecular analysis of integrated human papillomavirus 16 sequences in the cervical cancer cell line SiHa. Virology 1987, 159:389-398.